Cargando…
Antiviral mechanism of preclinical antimalarial compounds possessing multiple antiviral activities
We previously found that N‐89 and its derivative, N‐251, which are being developed as antimalarial compounds, showed multiple antiviral activities including hepatitis C virus (HCV). In this study, we focused on the most characterized anti‐HCV activity of N‐89(N‐251) to clarify their antiviral mechan...
Autores principales: | Gu, Weilin, Ueda, Youki, Dansako, Hiromichi, Satoh, Shinya, Kato, Nobuyuki |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8103717/ https://www.ncbi.nlm.nih.gov/pubmed/33977235 http://dx.doi.org/10.1096/fba.2020-00107 |
Ejemplares similares
-
Multiple antiviral activities of the antimalarial and anti-hepatitis C drug candidates N-89 and N-251
por: Ueda, Youki, et al.
Publicado: (2018) -
Establishment of Hepatitis C Virus RNA-Replicating Cell Lines Possessing Ribavirin-Resistant Phenotype
por: Satoh, Shinya, et al.
Publicado: (2015) -
New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication
por: Ueda, Youki, et al.
Publicado: (2013) -
Correction: New Preclinical Antimalarial Drugs Potently Inhibit Hepatitis C Virus Genotype 1b RNA Replication
por: Ueda, Youki, et al.
Publicado: (2013) -
ULBP1 is induced by hepatitis C virus infection and is the target of the NK cell‐mediated innate immune response in human hepatocytes
por: Dansako, Hiromichi, et al.
Publicado: (2018)